AR3 CAUSES AND EFFECTS OF SCENARIO REJECTION: STATED PREFERENCES FOR RHEUMATOID ARTHRITIS TREATMENTS
The purpose of this study is to quantify the correlates and consequences of scenario rejection in a study of stated preferences for rheumatoid arthritis (RA) treatments. METHODS: An on-line panel of RA patients completed a statedchoice survey. that required respondents to choose among ten pairs of treatment alternatives with different treatment features and a current-treatment alternative. Subjects who refuse to correctly complete the tradeoff tasks in a stated-preference survey may reject the hypothetical-treatment scenarios in 3 ways: refuse to answer any of the trade-off questions, answer all the ques-
Volume 10 • Number 3 • 2007 V A L U E I N H E A L T H PODIUM SESSION I: ARTHRITIS AR1 COST-EFFECTIVENESS OF ETANERCEPT AND INFLIXIMAB IN THE REAL-WORLD SETTING-AN ESTIMATE BASED ON PUBLISHED GERMAN DATA ON RESPONSE AND ADHERENCE
Ekelund M 1 , Deeg M 2 , Runge C 2 1 Wyeth AB, Solna, Sweden, 2 Wyeth Pharma GmbH, Münster, Germany OBJECTIVES: Anti-TNF-α drugs (Biologics) have become a cornerstone in the treatment of Rheumatoid Arthritis (RA). Since initial choice of agents is sometimes driven by expected treatment costs and related cost-effectiveness, we assessed the costeffectiveness of Etanercept (ETA) and Infliximab (INF) based on published real-world data from the German Biologics Registry.
METHODS:
We designed an excel-based cost-effectiveness model and calculated the costs per LUNDEX responder month. The LUNDEX score developed by Kristensen et al. (2006) is combining the proportion of patients fulfilling a selected response criterion (e.g. ACR 20) with the proportion of patients adhering to a therapy. Our model compares the costs per LUNDEX-response over six months for the treatment with ETA and INF from a payerperspective and calculates the cost per LUNDEX responder month. ACR 20 response rates (INF = 46%; ETA = 58%), adherence to therapy (INF = 77%, ETA = 82%) and real-world dosing data (INF = 4 mg/kg body weight, ETA = 47.5 mg/week) were derived from published registry data. Drug costs were calculated based on list prices. Administration and lab costs were derived from official databases. RESULTS: During the first six months, treatment with INF or ETA causes costs of EUR 10.873 € and EUR 9.683 €, respectively. The LUNDEX index at six months is 0.357 for INF and 0.477 for ETA. Accordingly, the costs per LUNDEX response are 30.277 € for INF and 20.167 € for ETA. The average cost per LUNDEX-responder month in Germany is €5.033 for INF and € 3.362 for ETA during the first six months of treatment. CONCLUSION: ETA is more cost-effective than INF in a real-world setting in Germany. Our cost-effectiveness analysis supports decision making based on a combined measure of response and therapy adherence. Long-term data on both response and adherence are needed to further assess real-world cost-effectiveness of Biologics. 
AR2 THE ASSOCIATION BETWEEN CO-EXISTING IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) AND HEALTH CARE COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) WHO RECEIVED ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS)

